Filing Details

Accession Number:
0001209191-21-024229
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-04-01 18:16:01
Reporting Period:
2021-03-30
Accepted Time:
2021-04-01 18:16:01
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1807120 Design Therapeutics Inc. DSGN () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1580787 Pratik Shah C/o Design Therapeutics, Inc.
6005 Hidden Valley Road, Suite 110
Carlsbad CA 92011
Executive Chairperson Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-03-30 25,000 $20.00 25,000 No 4 P Direct
Common Stock Acquisiton 2021-03-30 104,923 $0.00 129,923 No 4 C Indirect By Pratik Shah Living Trust (6/15/2011)
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
No 4 C Indirect By Pratik Shah Living Trust (6/15/2011)
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series A Preferred Stock Disposition 2021-03-30 171,025 $0.00 104,923 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
Footnotes
  1. The shares were purchased in the Issuer's initial public offering.
  2. All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 1.63 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date.
  3. The Reporting Person is the Trustee of the Pratik Shah Living Trust (6/15/2011). The Reporting Person disclaims beneficial ownership of these securities except to the extent of Reporting Person's pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.